KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) EBIT (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of EBIT data on record, last reported at -$41.2 million in Q4 2025.

  • For Q4 2025, EBIT rose 73.08% year-over-year to -$41.2 million; the TTM value through Dec 2025 reached -$553.9 million, down 16.77%, while the annual FY2025 figure was -$553.9 million, 16.77% down from the prior year.
  • EBIT reached -$41.2 million in Q4 2025 per PACB's latest filing, down from -$38.9 million in the prior quarter.
  • Across five years, EBIT topped out at -$33.7 million in Q1 2021 and bottomed at -$428.9 million in Q1 2025.
  • Average EBIT over 5 years is -$94.0 million, with a median of -$74.5 million recorded in 2021.
  • The widest YoY moves for EBIT: up 74.49% in 2025, down 427.19% in 2025.
  • A 5-year view of EBIT shows it stood at -$64.7 million in 2021, then crashed by 34.65% to -$87.1 million in 2022, then dropped by 0.53% to -$87.5 million in 2023, then tumbled by 74.79% to -$153.0 million in 2024, then surged by 73.08% to -$41.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$41.2 million in Q4 2025, -$38.9 million in Q3 2025, and -$44.9 million in Q2 2025.